Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1 - Full Text View

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000318

Purpose

The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine	Phase II

ChemIDplus related topics:

Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:	21
Study Start Date:	December 1995

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000318

Locations


United States, Connecticut
	APT Residential Services Division
	New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators


Principal Investigator:	Richard Schottenfeld, M.D.	Yale University

More Information

Study ID Numbers:	NIDA-09803-1, R01-09803-1
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000318
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Opioid-Related Disorders

Additional relevant MeSH terms:

Disease

Physiological Effects of Drugs

Narcotic Antagonists

Central Nervous System Depressants

Narcotics

Pharmacologic Actions

Pathologic Processes

Sensory System Agents

Therapeutic Uses

Analgesics

Peripheral Nervous System Agents

Central Nervous System Agents

Analgesics, Opioid

ClinicalTrials.gov processed this record on August 20, 2008